Markets · News reference
8-K filing — CENTERPOINT ENERGY HOUSTON ELECTRIC LLC
Filed: 2026-09-09 AccNo: 0001104659-26-106356 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Zscaler Stock Rocketed Higher This Week
Zscaler stock surged 20.7% this week after Bernstein raised its price target to $298 from $224, citing growing positive sentiment in the cybersecurity sector. The stock is trading at a discount to its historical valuation (25.8x operating cash flow vs. 5-year average of 47.6x), though Wedbush recently lowered its target to $215.
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Teva presented post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine formulation for schizophrenia treatment. Results showed over 56% of participants achieved stabilization, 21% achieved remission after 6+ months, and only 4% of stabilized patients relapsed. Data also demonstrated feasible switching strategies from oral or short-acting olanzapine formulations while maintaining therapeutic ranges. FDA approval is anticipated in Q4 2026.
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.
BMI Resins Market Advances as Aerospace Production Expands Demand for High-Temperature Composite Materials
The BMI Resins Market is projected to grow from USD 0.80 billion in 2025 to USD 1.29 billion by 2035, with a CAGR of 4.97%. Growth is driven by increased aerospace and defense manufacturing, hypersonic technologies, and electronics applications. North America dominates with 38.60% market share, while Asia Pacific shows the fastest growth at 8.80% CAGR.
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma announced on September 15, 2026, that its Compensation Committee granted inducement stock options to purchase 53,700 shares and 98,900 restricted stock units to newly hired employees. The stock options have a 10-year term with an exercise price of $31.93 per share and vest over four years, while RSUs vest equally over four years through 2030.